251 related articles for article (PubMed ID: 12859222)
21. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
Diabetes Prevention Program Research Group
Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
[TBL] [Abstract][Full Text] [Related]
22. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
24. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
27. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
Scheen AJ
Rev Med Liege; 2007 Jan; 62(1):48-52. PubMed ID: 17343130
[TBL] [Abstract][Full Text] [Related]
28. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada.
Boulin M; Diaby V; Tannenbaum C
PLoS One; 2016; 11(9):e0162951. PubMed ID: 27648831
[TBL] [Abstract][Full Text] [Related]
29. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
31. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
[TBL] [Abstract][Full Text] [Related]
32. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
33. A short term cost-effectiveness model for oral antidiabetic medicines in Europe.
Hood SC; Annemans L; Rutten-van Mölken M
Pharmacoeconomics; 1998 Mar; 13(3):317-26. PubMed ID: 10178657
[TBL] [Abstract][Full Text] [Related]
34. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
36. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets.
Moses RG
Clin Ther; 2008 Mar; 30(3):552-4. PubMed ID: 18405794
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Panikar V; Chandalia HB; Joshi SR; Fafadia A; Santvana C
J Assoc Physicians India; 2003 Nov; 51():1061-4. PubMed ID: 15260389
[TBL] [Abstract][Full Text] [Related]
40. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]